SuperworthGLAUKOS profit margin GKOS
Gross, operating and net profit as a share of revenue over the last twelve months, from 2014.
- Net margin, 12 months
- −30.7%
- Operating margin, 12 months
- −31.6%
- Net margin on a year earlier
- −9.3 pts
- Peer median
- 11.8%
Over the twelve months to Jun 30, 2026, GLAUKOS kept −30.7% of its revenue as net profit, with an operating margin of −31.6% and a gross margin of 60.7%.
Five years earlier its net margin was −21.2%.
The median for 10 medical instruments and supplies stocks of a similar size is 11.8%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | −37.0% | −39.3% | 55.7% |
| FY2024 | −38.2% | −31.9% | 75.5% |
| FY2023 | −42.8% | −40.9% | 76.0% |
| FY2022 | −35.1% | −29.1% | 75.6% |
| FY2021 | −16.9% | −11.2% | 77.3% |
| FY2020 | −53.5% | −54.9% | 59.2% |
| FY2019 | 6.5% | −21.2% | 83.7% |
| FY2018 | −7.1% | −7.2% | 86.2% |
| FY2017 | −0.1% | −1.4% | 86.8% |
| FY2016 | 4.0% | 3.7% | 85.9% |
| FY2015 | −51.9% | −14.4% | 81.9% |
| FY2014 | −26.6% | −28.9% | 75.0% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | −30.7% | −9.3 pts | −31.6% | |
| Q1 FY26 | −34.3% | −3.8 pts | −36.1% | |
| Q4 FY25 | −37.0% | +1.2 pts | −39.3% | |
| Q3 FY25 | −18.6% | +22.9 pts | −18.8% | |
| Q2 FY25 | −21.4% | +25.0 pts | −22.3% | |
| Q1 FY25 | −30.6% | +12.6 pts | −25.7% | |
| Q4 FY24 | −38.2% | +4.6 pts | −31.9% | |
| Q3 FY24 | −41.5% | +1.1 pts | −36.7% | |
| Q2 FY24 | −46.4% | −3.8 pts | −39.7% | |
| Q1 FY24 | −43.2% | +5.0 pts | −41.3% | |
| Q4 FY23 | −42.8% | −7.7 pts | −40.9% | |
| Q3 FY23 | −42.6% | −11.2 pts | −40.8% |
Against its peers
Companies in Medical - Instruments & Supplies nearest GLAUKOS' size, closest first, today.
| Company | Profit margin |
|---|---|
| GKOSGLAUKOS | −30.7% |
| PODDInsulet | 12.3% |
| GMEDGlobus Medical | 17.0% |
| ALGNAlign Technology | 10.0% |
| COOCooper Companies | 13.5% |
| PENPenumbra | 10.7% |
| SOLVSolventum | 17.3% |
| MSAMSA Safety | 16.1% |
| MMSIMerit Medical Systems | 9.2% |
| HAEHaemonetics | 7.1% |
| VNTVontier | 11.3% |
| Peer median | 11.8% |
Where GLAUKOS ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on GLAUKOS
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.